Ernexa Therapeutics (ERNA) Reports Clean IND-Enabling Safety Data, Targets Q4 2026 IND
Ernexa Therapeutics reported favorable repeat-dose tox, tumorigenicity and biodistribution results for ERNA-101 and said GMP manufacturing is underway, with an IND submission planned for Q4 2026 for platinum-resistant ovarian cancer.Material DetailsContext by AI AnalystThis is an early-stage de-ris…